• 1
    Rouprêt M, Zigeuner R, Palou J et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 Update. Eur Urol 2011; 59: 584594
  • 2
    Chen GL, Bagley DH. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 2000; 164: 11731176
  • 3
    Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010; 183: 21482153
  • 4
    Lughezzani G, Jeldres C, Isbarn H et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 2009; 45: 32913297
  • 5
    Li CC, Chang TH, Wu WJ et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008; 54: 11271135
  • 6
    Roscigno M, Shariat SF, Margulis V et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009; 181: 24822489
  • 7
    Miyao N, Masumori N, Takahashi A et al. Lymph node metastasis in patients with carcinomas of the renal pelvis and ureter. Eur Urol 1998; 33: 180185
  • 8
    Brausi MA, Gavioli M, De Luca G et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol 2007; 52: 14141420
  • 9
    Roscigno M, Cozzarini C, Bertini R et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol 2008; 53: 794802
  • 10
    Matin SF, Margulis V, Kamat A et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 31273134
  • 11
    Youssef RF, Shariat SF, Lotan Y et al. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2011; 108: 12861291
  • 12
    Isbarn H, Jeldres C, Shariat SF et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 2009; 182: 21772181
  • 13
    Lughezzani G, Sun M, Perrotte P et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results Database. Urology 2010; 75: 321327
  • 14
    Mungan NA, Kiemeney LA, van Dijck JA et al. Gender differences in stage distribution of bladder cancer. Urology 2000; 55: 368371
  • 15
    Yu W, Zhao YY, Shen Q et al. Gender-related differences in pathological characteristics of upper urinary tract urothelial carcinoma: analysis of 597 cases. Beijing Da Xue Xue Bao 2011; 43: 522524
  • 16
    Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999; 85: 13421344
  • 17
    Yang MH, Chen KK, Yen CC et al. Unusually high incidence of upper tract urothelial carcinoma in Taiwan. Urology 2002; 59: 681687
  • 18
    Wu MC , Wu ZD eds. Huang Jia Si Surgery, 7th edn. Beijing: People's Medical Publishing House, 2008: 2360
  • 19
    Ma YC, Zuo L, Chen JH et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 29372944
  • 20
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1266
  • 21
    Chromecki TF, Cha EK, Fajkovic H et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 2012; 61: 245253
  • 22
    Lai MN, Wang SM, Chen PC et al. Population-based case–control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179186
  • 23
    Lai MN, Lai JN, Chen PC et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology 2009; 14: 227234
  • 24
    Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74: 158169
  • 25
    Margulis V, Youssef RF, Karakiewicz PI et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 2010; 184: 453458
  • 26
    Raman JD, Ng CK, Scherr DS et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010; 57: 10721079
  • 27
    Fritsche HM, Novara G, Burger M et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 2012; 30: 666672
  • 28
    Favaretto RL, Shariat SF, Savage C et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 2012; 109: 7782
  • 29
    Messer JC, Terrell JD, Herman MP et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 2011 Sep 7. [Epub ahead of print]. DOI:10.1016/j.urolonc.2011.07.011